RxDoctor Payments Data

Renee Schnupp, PA

Physician Assistant · Brooklyn, OHNPI 1003290883

Payments from drug & device makers

$4,194in general payments, 2019–2025

Across 206 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$331
  • Takeda Pharmaceuticals U.S.A., Inc.$289
  • Ardelyx, Inc.$240
  • Nestle Healthcare Nutrition Inc.$212
  • Johnson & Johnson$209
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,194 in reported general payments places this provider in the 90th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$7,297
Medicare patients
76
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab30$854,941
Humira(Cf)Adalimumab13$77,838
LinzessLinaclotide67$52,708
MotegrityPrucalopride Succinate31$17,966
TrulancePlecanatide26$16,989
Mesalamine29$15,438
Alosetron Hcl12$11,512
Dexlansoprazole DrDexlansoprazole42$8,797
Ursodiol14$4,786
Mesalamine ErMesalamine15$4,259
Pantoprazole Sodium267$3,069
Lubiprostone20$2,655
Esomeprazole Magnesium65$1,850
Omeprazole161$1,821
Sucralfate19$428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$209$854,94130 claims
AbbVieHumira(Cf), Linzess$1,214$130,54580 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$289$17,96631 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$103$16,98926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Brooklyn

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →